Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: A randomized, double blind, parallel group, dose ranging study

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages

  Dogra, S ^a   Jain, A ^a   Kanwar, A J ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLURRED VISION; CHEILITIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MELENA; MYALGIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA SEVERITY INDEX SCORE; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; XEROPHTHALMIA; XEROSTOMIA;

ACITRETIN; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PSORIASIS; YOUNG ADULT;

EID: 84874108809     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04644.x     Document Type: Article

References (28)

1. Farber EM, Nall ML,. Epidemology: natural history and genetics. In:, Roenigk HH, Maibach HI, eds. Psoriasis, 3rd edn. Marcel Dekker, New York, 1998: 107-158.
2. Kaur I, Handa S, Kumar B,. Natural history of psoriasis: a study from Indian subcontinent. J Dermatol 1997; 24: 230-234.
3. Lebwohl M, Menter A, Koo J, Feldman SR,. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50: 416-430.
4. Wiegand UW, Chou RC,. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 1998; 39: S25-S33.
5. Vieira AV, Schneider WJ, Vieira PM,. Retinoids: transport, metabolism and mechanism of action. J Endocrinol 1995; 146: 201-207.
6. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis: results of a Nordic multicentre study. Acta Dermatol Venereol 1989; 69: 35-40.
7. Olsen EA, Weed WW, Meyer CJ, Cobo LM,. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol 1989; 21: 681-686.
8. Torok L, Kadar L, Geiger JM,. Acitretin treatment of severe psoriasis. Acta Dermatol Venereol Suppl (Stockh) 1989; 146: 104-106.
9. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicentre trial. J Am Acad Dermatol 1991; 24: 598-602.
10. Geiger JM, Czarnetzki BM,. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica 1988; 176: 182-190.
11. Lassus A, Geiger JM, Nyblom M, et al. Treatment of severe psoriasis with etretin (Ro 10-1670). Br J Dermatol 1987; 117: 333-341.
12. Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in dose dependent fashion. J Am Acad Dermatol 1998; 18: 655-662.
13. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicentre study. J Am Acad Dermatol 1988; 19: 458-468.
14. Yamauchi PS, Rizk D, Lowe NJ,. Retinoid therapy for psoriasis. Dermatol Clin 2004; 22: 467-476.
15. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242.
16. Giguere V,. Retinoic acid receptors and cellular retinoid binding protein:complex interplay in retinoid signalling. Endocr review 1994; 15: 61-79.
17. Berbis P, Geiger JM, Vaisse C, et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatolgica 1989; 178: 88-92.
18. ® (acitretin) capsules: data sheet [online] URL http://www.roche.co.nz/products/medicine/24 (last accessed: 10 May 2008).
19. Carlo P, Marco P, Riccardo GB,. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Exp Dermatol 2009; 18: 337-349.
20. Mittal R, Malhotra S, Pandhi P, et al. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis. Arch Dermatol 2009; 145: 387-393.
21. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
22. Baran R,. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148-152.
23. Lebwohl M, Ali S,. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.
24. Pearce DJ, Klinger S, Ziel KK, et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 2006; 142: 1000-1004.
25. Tey HL, Theng TS,. Acitretin induced bipedal edema. J Dermatol 2006; 33: 372-374.
26. Geiger J, Saurat JH,. Acitretin and etretinate: how and when they should be used. Dermatol Clin 1993; 11: 117-129.
27. Ling MR,. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999; 41: S13-S17.
28. Dunn LK, Gaar LR, Yentzer BA, O'Neill JL, Feldman SR,. Acitretin in dermatology: a review. J Drugs Dermatol 2011; 10: 772-782.